In CRC, it has been reported that using a highly sensitive in vitro stimulation method and specific CD8+ peripheral blood memory T cells empowerment targeting the SMAD5 and mucin 4 (MUC4) neoantigens could be effective in the development of personalized NRT‐based immunotherapy.[95] Due to identifying recurrent neoantigen in CRC, a study used WES on 1779 data obtained from seven published CRC cohort studies. Here, CD8A is linked to colorectal carcinoma.